Equivalentie design: Difference between revisions

From Wikistatistiek
Jump to navigation Jump to search
No edit summary
No edit summary
Line 9: Line 9:
*[http://www.annals.org/cgi/content/full/133/6/464 Ellenberg SS, Temple R., Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases, Ann Intern Med. 2000 Sep 19;133(6):464-70]
*[http://www.annals.org/cgi/content/full/133/6/464 Ellenberg SS, Temple R., Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases, Ann Intern Med. 2000 Sep 19;133(6):464-70]


*[http://www.emea.europa.eu/pdfs/human/ewp/215899en.pdf GUIDELINE ON THE CHOICE OF THE NON-INFERIORITY MARGIN (CHMP), EMEA/CPMP/EWP/2158/99 July 2005]
*[http://www.emea.europa.eu/pdfs/human/ewp/215899en.pdf Guideline on the choice of the non-inferiority margin(CHMP), EMEA/CPMP/EWP/2158/99 July 2005]





Revision as of 11:52, 9 September 2009